DOCSLIB.ORG

Glutaric Aciduria Type I a Guide for Parents and Patients

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Glutaric Aciduria Type I a Guide for Parents and Patients GLUTARIC ACIDURIA TYPE I A GUIDE FOR PARENTS AND PATIENTS CENTRE FOR PAEDIATRIC AND ADOLESCENT MEDICINE ANGELIKA-LAUTENSCHLÄGER CHILDREN'S HOSPITAL METABOLIC CENTRE UK HD Book-Open CONTENTS 4 | PREFACE AND OBJECTIVE OF THE GUIDE 6 | INTRODUCTION 6 Diagnosis 8 Natural disease course 10 Pathogenesis 12 Diet and carnitine 14 Emergency treatment 18 Treatment of movement disorders IMPRINT Publisher 20 | NUTRITION AND DIET Heidelberg University Hospital 20 Composition of our food 21 Food classification for the low-lysine diet Editors 23 Composition of the diet Dr. Nikolas Boy Prof. Dr. Stefan Kölker Katja Sahm 24 | PRINCIPLE OF DIETARY TREATMENT 26 Amino acid supplement Design and layout Corporate Communications of the Heidelberg University Hospital and Medical Faculty 28 | PRACTICAL APPLICATION OF THE DIET www.klinikum.uni-heidelberg.de/Unternehmenskommunikation 28 Diet for infants Eva Tuengerthal, graphics/layout 30 Food classification Photos photocase.com / Francesca Schellhaas / nonmim / b-fruchten / 34 | PATIENTS WITH MOVEMENT DISORDERS cw_design / Julia Straub / view7 / a_sto istockphoto.com 35 | EMERGENCY TREATMENT 35 Emergency dietary treatment at home Print Nino Druck GmbH, Heidelberg 36 | EXAMPLE DIETARY PLANS Translation Kindly supported by 40 | DIET AFTER THE AGE OF 6 YEARS 44 | FOOD COMPOSITION AND NUTRITION TABLE FOR CALCULATING THE LYSINE CONTENT Last updated 54 | BIBLIOGRAPHY November 2018 3 | 3 3 | 3 4 | 5 PREFACE AND OBJECTIVE CURRENT GUIDELINE FOR OF THE GUIDE GLUTARIC ACIDURIA TYPE I Your child (or you) has been diagnosed with glutaric aciduria type I. All recommendations given in this guide conform to the current guide- Dr. Nikolas Boy This diagnosis has certainly raised a number of questions and may line (AWMF Guideline No. 027/018, highest quality class “S3”, i.e. ev- Chairman of the Guideline Development Group since 2015 also have given rise to some concerns. You have probably neither idence- and consensus-based guideline) for the “Diagnosis, Therapy heard of this inherited metabolic disorder before, nor do you know and Management of Glutaric Aciduria Type I (synonym: glutaryl-CoA Prof. Dr. Stefan Kölker anyone else who has been diagnosed with this disease. Moreover, you dehydrogenase deficiency)”. The guideline was developed by an in- Head of the Division of Neuropaediatrics and Metabolic Medicine and may find it difficult to “understand” this disease, especially if your ternational guideline development group and published for the first Chairman of the Guideline Development Group 2003–2015 child (or you) does not show any apparent signs or symptoms. time in 2007. Besides Germany, the guideline also became a national therapy guideline in other countries (including Italy, Portugal and the Katja Sahm This 2nd updated edition of this guide is therefore directed primarily at Netherlands). Dietician parents and patients. It is designed to answer the most frequent ques- tions, give you a general idea of what glutaric aciduria type I is and The first revision of the guideline (2011) was based mainly on the re- how this disease is treated according to the present state of knowl- sults of a study on 52 patients who were identified by newborn screen- IN COLLABORATION WITH edge. Secondly, this guide is addressed to all professional groups that ing in Germany. This study was the first to demonstrate the positive provide treatment to children, adolescents and adults with glutaric effect of guideline-based treatment on the clinical outcome (Heringer Petra Schick aciduria type I. et al. 2010). This was taken as a basis for developing the 1st edition Dietitian of this guide for parents. Over the last few years, collaboration on a We hope that this guide will provide you with additional, hands-on national and international scale has made it possible to further expand Privatdozent Dr. Peter Burgard support during the daily treatment. However, this guide is in no way the knowledge on the disease and further increase the evidence level Head Psychologist intended to replace a structured initial consultation or the medical of the guideline recommendations. care and continuous training provided by the experienced team of a Prof. Dr., Prof. h.c. (RCH) Georg F. Hoffmann metabolic centre. Any change in the treatment should always be made In 2016, the guideline was revised for the second time, which forms Medical Director in consultation with the attending team of metabolic experts. the basis for this 2nd updated edition of the guide for parents. The current guideline still has the highest AWMF quality class “S3”. It con- Centre for Paediatric and Adolescent Medicine solidates the more than thirty years of experience of international Angelika-Lautenschläger Children's Hospital experts and meets the high requirements for objectivity, transparency, Department I evidence base and consensus development. In addition, the guideline Division of Neuropaediatrics and Metabolic Medicine takes into account additional criteria that are important for the treat- Metabolic Centre ment process, such as clinical relevance and experience, consistency Im Neuenheimer Feld 430 of evidence, benefits and risks for the patient, the perspective of the 69120 Heidelberg, Germany patient and the families, ethical, legal and economic aspects, the ap- plicability to the German health care system as well as practicability ENVELOPE in daily life. According to the present state of knowledge, the current [email protected] guideline recommendations are the most effective to best protect your [email protected] child's (or your) health and development. The complete guideline can [email protected] be obtained via the online portal of the Association of the Scientific Medical Societies in Germany (AWMF) (www.awmf.org/; main menu: P.S.: We will be happy to receive any suggestions for continuously “Guidelines”). It predominantly addresses all professional groups that improving the brochure. provide treatment to patients with glutaric aciduria type I. Even though the guideline and this guide have been prepared with the utmost care, they may contain inconsistencies or even mistakes. In ad- dition, not all patients may benefit fromProf. the Dr. recommended A. Unterberg treatment to the same extent. Therefore, no guaranteeÄrztlicher can be Direktorgiven as to the use of this guide and the therapeutic outcome. The practical implementa- tion of the recommended treatment and the associated duty of care are solely incumbent upon the attending physician. Kind regards, 5 | 5 6 | 7 GLUTARIC ACIDURIA TYPE I A GUIDE FOR PARENTS AND PATIENTS INTRODUCTION DIAGNOSIS Hand-point-right If there is a confirmed diagnosis of glutaric aciduria type I, other family members (in particular siblings and parents) of the affected patient should be specifically tested for the disease as well. WHAT DOES “GLUTARIC ACIDURIA TYPE I” MEAN? HOW IS THE DISEASE DIAGNOSED? tested for glutaric aciduria type I as part of the early detec- CAN OTHER FAMILY MEMBERS ALSO BE AFFECTED BY The term “glutaric aciduria” means “presence of glutaric Besides increased excretion of glutaric acid, glutaric ac- tion screening since 1 April 2005. On average, about 6–7 THE DISEASE? acid in the urine”. Glutaric acid is an intermediate break- iduria type I involves the presence of other substances in newborns are diagnosed with glutaric aciduria type I in Ger- Yes, this is possible. Since the disease is inherited, other down product of human metabolism. It is usually present the urine and other body fluids, such as 3-hydroxyglutaric many every year, which is equivalent to a prevalence of one close family members may be affected as well. This may in the body in small quantities only and is excreted in the acid and glutarylcarnitine. In people who are not affected newborn with glutaric aciduria type I in 120,000 newborns even be the case if no apparent symptoms are present in urine. Increased excretion of glutaric acid had already been by the disease, these substances are present in the body (1:120,000). them. observed in patients with glutaric aciduria before the ac- and blood in very small quantities only and are excreted in tual cause of the disease was discovered more than 40 the urine. These small quantities are also referred to as the To ultimately confirm the diagnosis, additional testing is years ago. This first-observed biochemical symptom gave “normal range” or “reference range”. In affected patients, necessary (molecular-genetic and, if necessary, enzymatic the disease its name. Since there are other diseases in- by contrast, these substances are present in increased con- testing). volving increased excretion of glutaric acid, these diseases centrations, which are often many times above the normal were classified into three types (type I, type II and type III). range. As a result, most affected children can already be This guide exclusively addresses glutaric aciduria type I. reliably identified by newborn screening. According to the Even though the names glutaric aciduria type II and type III German national guidelines for newborn screening (ww- sound very similar, they are different diseases, which must w.g-ba.de: Guidelines for children: Expanded newborn 7 | 7 not be confused with glutaric aciduria type I. screening), all newborns throughout Germany have been 8 | 9 GLUTARIC ACIDURIA TYPE I A GUIDE FOR PARENTS AND PATIENTS INTRODUCTION NATURAL DISEASE COURSE HOW DOES THE DISEASE MANIFEST? Adolescents and adults OTHER DISEASE FORMS By now, individual adolescents and adults with glutaric ac- In addition, there are individual patients who develop Newborns and young infants iduria type I have been identified who have come through insidious neurological symptoms without experiencing an Most newborns and young infants with glutaric aciduria childhood unscathed, despite not having been diagnosed acute crisis event (insidious-onset type). These patients are type I do not develop any symptoms and cannot be dis- and treated (“late-onset type”). The physical symptoms in usually affected by a milder form of dystonia than patients tinguished from healthy children of the same age.
Load more

Recommended publications
  • Newborn Screening Laboratory Manual of Services
    Newborn Screening Laboratory Manual of Services Test Panel: Please see the following links for a detailed description of testing in the Newborn Screening section. Information about the Newborn Screening program is available here. Endocrine Disorders Congenital adrenal hyperplasia (CAH) Congenital hypothyroidism (TSH) Hemoglobinopathies Sickle cell disease (FS) Alpha (Barts) Sickle βeta Thalassemia (FSA) Other sickling hemoglobinopathies such as: FAS FAC FAD FAE Homozygous conditions such as: FC FD FE Metabolic Disorders Biotinidase deficiency Galactosemia Cystic fibrosis (CF) first tier screening for elevated immunoreactive trypsinogen (IRT) Cystic fibrosis second tier genetic mutation analysis on the top 4% IRT concentrations. Current alleles detected : F508del, I507del, G542X, G85E, R117H, 621+1G->T, 711+1G->T, R334W, R347P, A455E, 1717-1G->A, R560T, R553X, G551D, 1898+1G->A, 2184delA, 2789+5G->A, 3120+1G->A, R1162X, 3659delC, 3849+10kbC->T, W1282X, N1303K, IVS polyT T5/T7/T9 *Currently validating a mutation panel that includes the above alleles in addition to the following: 1078delT, Y122X, 394delTT, R347H, M1101K, S1255X, 1898+5G->T, 2183AA->G, 2307insA, Y1092X, 3876delA, 3905insT, S549N, S549R_1645A->C, S549R-1647T->G, S549R-1647T->G, V520F, A559T, 1677delTA, 2055del9->A, 2143delT, 3199del6, 406-1G->A, 935delA, D1152H, CFTRdele2, E60X, G178R, G330X, K710X, L206W, Q493X, Q890X, R1066C, R1158X, R75X, S1196X, W1089X, G1244E, G1349D, G551S, R560KT, S1251N, S1255P Amino acid disorders Phenylketonuria (PKU) / Hyperphenylalaninemia Maple
    [Show full text]
  • Toxicological Basis Data for the Derivation of EU-LCI Values For
    TEXTE 223/2020 Toxicological basis data for the derivation of EU- LCI values for neopentyl glycol, diisobutyl succinate, diisobutyl glutarate, 1,2- dimethoxyethane and 1,2-diethoxyethane Final report German Environment Agency TEXTE 223/2020 Ressortforschungsplan of the Federal Ministry for the Enviroment, Nature Conservation and Nuclear Safety Project No. (FKZ) 3719 62 205 0 Report No. FB000359/ENG Toxicological basis data for the derivation of EU-LCI values for neopentyl glycol, diisobutyl succinate, diisobutyl glutarate, 1,2- dimethoxyethane and 1,2-diethoxyethane Final report by Dr. Barbara Werschkun Wissenschaftsbüro, Berlin On behalf of the German Environment Agency Imprint Publisher Umweltbundesamt Wörlitzer Platz 1 06844 Dessau-Roßlau Tel: +49 340-2103-0 Fax: +49 340-2103-2285 [email protected] Internet: www.umweltbundesamt.de /umweltbundesamt.de /umweltbundesamt Report performed by: Wissenschaftsbüro Dr. Barbara Werschkun Monumentenstr. 31a 10829 Berlin Germany Report completed in: May 2020 Edited by: Section II 1.3 Indoor Hygiene, Health-related Environmental Impacts Dr. Ana Maria Scutaru Publication as pdf: http://www.umweltbundesamt.de/publikationen ISSN 1862-4804 Dessau-Roßlau, December 2020 The responsibility for the content of this publication lies with the author(s). TEXTE Toxicological basis data for the derivation of EU-LCI values for neopentyl glycol, diisobutyl succinate, diisobutyl glutarate, 1,2-dimethoxyethane and 1,2-diethoxyethane – Final report Abstract: Toxicological basis data for the derivation of EU-LCI values for neopentyl glycol, diisobutyl succinate, diisobutyl glutarate, 1,2-dimethoxyethane and 1,2-diethoxyethane The objective of this study was the evaluation of toxicological data for five substances as basis for the derivation of EU-LCI values.
    [Show full text]
  • Glutaric Aciduria Lactic Acidosis Glutaryl-Coa Dehydrogenase Deficiency Short-Chain Monocarboxylic Acids
    Pediat. Res. 13: 977-981 (1979) C6-C l~-dicarboxylicacid ketosis glutaric aciduria lactic acidosis glutaryl-CoA dehydrogenase deficiency short-chain monocarboxylic acids Ketotic Episodes in Glutaryl-CoA Dehydrogenase Deficiency (Glutaric Aciduria) NIELS GREGERSEN AND NIELS JACOB BRANDT Research Laboratory for Metabolic Disorders, University Department of Clinical Chemistry, Aarhus Kommunehospital, Aarhus, and Section of Clinical Genetics, University Department of Paediatrics, Obstetrics, and Gynaecology, Rigshospitalet, Copenhagen, Denmark Summaw the ketoacidosis, a pronounced lactic acidosis and lactic aciduria is seen in most cases. The present report, together with a recent A 7-yr-old boy with glutaryl-CoA dehydrogenase deficiency (glu- report of Goodman et al. (7), indicates that glutaryl-CoA dehy- taric aciduria), presenting periodic episodes of lethargy and keto- drogenase deficiency (glutaric aciduria) may present ketotic epi- sis, was studied during two such episodes. The urinary excretions sodes, similar to those of the other organic acidurias. of glutaric and 3-OH-glutaric acids were 3100-7900 and 460-660 The patient described by Goodman et al. (7) died in a Reye's &mg creatinine, respectively, during these episodes. Urine sam- syndromelike state. Our patient has had two episodes of ketosis ples collected before and after the attacks contained 100-5300 and and lethargy. During these episodes, the urinary metabolic profiles 230-370 &mg creatinine of glutaric acid and 3-OH-glutaric of organic acids were studied in detail, in an attempt to elucidate acids, respectively. During the episodes, glutaconic acid excretion the pathogenic mechanism leading to the severe clinical and rose from 14-89 to 93-630 pg/mg creatinine.
    [Show full text]
  • Glutaric Acidemia Type 1
    Glutaric acidemia type 1 What is glutaric acidemia type 1? Glutaric acidemia type 1 is an inherited disease characterized by episodes of severe brain dysfunction that result in spasticity, low muscle tone, and seizures.1,2 Individuals with glutaric acidemia type 1 have defects in the glutaryl-CoA dehydrogenase enzyme, which breaks down the amino acids lysine, hydroxylysine, and tryptophan. The symptoms of glutaric acidemia type 1 are due to the build-up of these amino acids and their metabolites in the body, primarily affecting the brain.1 Glutaric acidemia type 1 is also known as glutaric aciduria type 1.2 What are the symptoms of glutaric acidemia type 1 and what treatment is available? The severity of symptoms of glutaric acidemia type 1 can vary widely, even within families. Newborns may have macrocephaly (large head size) with no other signs or symptoms. Symptoms typically begin within months after birth and are often triggered by illness or fasting. Symptoms may include2: • Hypotonia (low muscle tone) • Feeding difficulties • Poor growth • Swelling of the brain • Spasticity (abnormally tight muscles) • Dystonia (sustained muscle contractions causing twisting movements and abnormal posture) • Seizures • Developmental delays • Coma, and possibly death, especially if untreated Individuals tend to have a reduced life expectancy. Approximately 10% of individuals die within the first decade; more than half do not survive past 35 years of age. 3 There is no cure for glutaric acidemia type 1, and treatment is aimed at preventing episodes of brain dysfunction and seizures. Treatment generally includes a low protein diet and nutrition supplements, and a feeding tube may be required for some individuals.
    [Show full text]
  • Microwave-Assisted Low-Temperature Dehydration Polycondensation of Dicarboxylic Acids and Diols
    Polymer Journal (2011) 43, 1003–1007 & The Society of Polymer Science, Japan (SPSJ) All rights reserved 0032-3896/11 $32.00 www.nature.com/pj RAPID COMMUNICATION Microwave-assisted low-temperature dehydration polycondensation of dicarboxylic acids and diols Polymer Journal (2011) 43, 1003–1007; doi:10.1038/pj.2011.107; published online 26 October 2011 INTRODUCTION time (4100 h). Therefore, we next focused on has been no report concerning a Currently, because of increasing concerns identifying more active catalysts and found that non-thermal effect in microwave-assisted about damage to the environment, the devel- scandium and thulium bis(nonafluorobutane- polycondensation reactions,33,34 although opment of new, eco-friendly (industrially sulfonyl)imide ((Sc(NNf2)3) and (Tm(NNf2)3)) there has been a report that non-thermal relevant) chemical reactions and materials is were more efficient catalysts and allowed us microwaves have a role in the chain polymer- crucial. Aliphatic polyesters have attracted to obtain high-molecular-weight polyesters ization of a lactone.32 Therefore, we studied 4 much interest as environmentally benign, (Mn42.0Â10 ) from adipic acid (AdA) and microwave-assisted syntheses of polyesters at biodegradable polymers.1,2 In general, alipha- 3-methyl-1,5-pentanediol (MPD) at 60 1Cina a relatively low temperature (80 1C) using a tic polyesters are commercially produced by shortperiodoftime(24h)andwithasmaller microwave chamber equipped with a tem- polycondensation of a dicarboxylic acid and a amount of catalyst (0.1 mol%) than had pre- perature control, and the results are reported 1.1–1.5 mol excess of a diol at a temperature viously been possible.26 herein.
    [Show full text]
  • Glutaric Acid Production by Systems Metabolic Engineering of an L-Lysine–Overproducing Corynebacterium Glutamicum
    Glutaric acid production by systems metabolic engineering of an L-lysine–overproducing Corynebacterium glutamicum Taehee Hana, Gi Bae Kima, and Sang Yup Leea,b,c,1 aMetabolic and Biomolecular Engineering National Research Laboratory, Systems Metabolic Engineering and Systems Healthcare Cross-Generation Collaborative Laboratory, Department of Chemical and Biomolecular Engineering (BK21 Plus Program), Institute for the BioCentury, Korea Advanced Institute of Science and Technology, Yuseong-gu, 34141 Daejeon, Republic of Korea; bBioInformatics Research Center, Korea Advanced Institute of Science and Technology, Yuseong-gu, 34141 Daejeon, Republic of Korea; and cBioProcess Engineering Research Center, Korea Advanced Institute of Science and Technology, Yuseong-gu, 34141, Daejeon, Republic of Korea Contributed by Sang Yup Lee, October 6, 2020 (sent for review August 18, 2020; reviewed by Tae Seok Moon and Blake A. Simmons) There is increasing industrial demand for five-carbon platform processes rely on nonrenewable and toxic starting materials, chemicals, particularly glutaric acid, a widely used building block however. Thus, various approaches have been taken to biologi- chemical for the synthesis of polyesters and polyamides. Here we cally produce glutaric acid from renewable resources (13–19). report the development of an efficient glutaric acid microbial pro- Naturally, glutaric acid is a metabolite of L-lysine catabolism in ducer by systems metabolic engineering of an L-lysine–overproducing Pseudomonas species, in which L-lysine is converted to glutaric Corynebacterium glutamicum BE strain. Based on our previous study, acid by the 5-aminovaleric acid (AVA) pathway (20, 21). We an optimal synthetic metabolic pathway comprising Pseudomonas previously reported the development of the first glutaric acid- putida L-lysine monooxygenase (davB) and 5-aminovaleramide amido- producing Escherichia coli by introducing this pathway compris- hydrolase (davA) genes and C.
    [Show full text]
  • APPENDIX G Acid Dissociation Constants
    harxxxxx_App-G.qxd 3/8/10 1:34 PM Page AP11 APPENDIX G Acid Dissociation Constants §␮ ϭ 0.1 M 0 ؍ (Ionic strength (␮ † ‡ † Name Structure* pKa Ka pKa ϫ Ϫ5 Acetic acid CH3CO2H 4.756 1.75 10 4.56 (ethanoic acid) N ϩ H3 ϫ Ϫ3 Alanine CHCH3 2.344 (CO2H) 4.53 10 2.33 ϫ Ϫ10 9.868 (NH3) 1.36 10 9.71 CO2H ϩ Ϫ5 Aminobenzene NH3 4.601 2.51 ϫ 10 4.64 (aniline) ϪO SNϩ Ϫ4 4-Aminobenzenesulfonic acid 3 H3 3.232 5.86 ϫ 10 3.01 (sulfanilic acid) ϩ NH3 ϫ Ϫ3 2-Aminobenzoic acid 2.08 (CO2H) 8.3 10 2.01 ϫ Ϫ5 (anthranilic acid) 4.96 (NH3) 1.10 10 4.78 CO2H ϩ 2-Aminoethanethiol HSCH2CH2NH3 —— 8.21 (SH) (2-mercaptoethylamine) —— 10.73 (NH3) ϩ ϫ Ϫ10 2-Aminoethanol HOCH2CH2NH3 9.498 3.18 10 9.52 (ethanolamine) O H ϫ Ϫ5 4.70 (NH3) (20°) 2.0 10 4.74 2-Aminophenol Ϫ 9.97 (OH) (20°) 1.05 ϫ 10 10 9.87 ϩ NH3 ϩ ϫ Ϫ10 Ammonia NH4 9.245 5.69 10 9.26 N ϩ H3 N ϩ H2 ϫ Ϫ2 1.823 (CO2H) 1.50 10 2.03 CHCH CH CH NHC ϫ Ϫ9 Arginine 2 2 2 8.991 (NH3) 1.02 10 9.00 NH —— (NH2) —— (12.1) CO2H 2 O Ϫ 2.24 5.8 ϫ 10 3 2.15 Ϫ Arsenic acid HO As OH 6.96 1.10 ϫ 10 7 6.65 Ϫ (hydrogen arsenate) (11.50) 3.2 ϫ 10 12 (11.18) OH ϫ Ϫ10 Arsenious acid As(OH)3 9.29 5.1 10 9.14 (hydrogen arsenite) N ϩ O H3 Asparagine CHCH2CNH2 —— —— 2.16 (CO2H) —— —— 8.73 (NH3) CO2H *Each acid is written in its protonated form.
    [Show full text]
  • Orphanet Report Series Rare Diseases Collection
    Marche des Maladies Rares – Alliance Maladies Rares Orphanet Report Series Rare Diseases collection DecemberOctober 2013 2009 List of rare diseases and synonyms Listed in alphabetical order www.orpha.net 20102206 Rare diseases listed in alphabetical order ORPHA ORPHA ORPHA Disease name Disease name Disease name Number Number Number 289157 1-alpha-hydroxylase deficiency 309127 3-hydroxyacyl-CoA dehydrogenase 228384 5q14.3 microdeletion syndrome deficiency 293948 1p21.3 microdeletion syndrome 314655 5q31.3 microdeletion syndrome 939 3-hydroxyisobutyric aciduria 1606 1p36 deletion syndrome 228415 5q35 microduplication syndrome 2616 3M syndrome 250989 1q21.1 microdeletion syndrome 96125 6p subtelomeric deletion syndrome 2616 3-M syndrome 250994 1q21.1 microduplication syndrome 251046 6p22 microdeletion syndrome 293843 3MC syndrome 250999 1q41q42 microdeletion syndrome 96125 6p25 microdeletion syndrome 6 3-methylcrotonylglycinuria 250999 1q41-q42 microdeletion syndrome 99135 6-phosphogluconate dehydrogenase 67046 3-methylglutaconic aciduria type 1 deficiency 238769 1q44 microdeletion syndrome 111 3-methylglutaconic aciduria type 2 13 6-pyruvoyl-tetrahydropterin synthase 976 2,8 dihydroxyadenine urolithiasis deficiency 67047 3-methylglutaconic aciduria type 3 869 2A syndrome 75857 6q terminal deletion 67048 3-methylglutaconic aciduria type 4 79154 2-aminoadipic 2-oxoadipic aciduria 171829 6q16 deletion syndrome 66634 3-methylglutaconic aciduria type 5 19 2-hydroxyglutaric acidemia 251056 6q25 microdeletion syndrome 352328 3-methylglutaconic
    [Show full text]
  • Glutaric Acidemia Type 1: Treatment and Outcome of 168 Patients Over Three Decades
    University of Massachusetts Medical School eScholarship@UMMS Open Access Publications by UMMS Authors 2020-11-01 Glutaric acidemia type 1: Treatment and outcome of 168 patients over three decades Kevin A. Strauss University of Massachusetts Medical School Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/oapubs Part of the Congenital, Hereditary, and Neonatal Diseases and Abnormalities Commons, Nutritional and Metabolic Diseases Commons, and the Pediatrics Commons Repository Citation Strauss KA. (2020). Glutaric acidemia type 1: Treatment and outcome of 168 patients over three decades. Open Access Publications by UMMS Authors. https://doi.org/10.1016/j.ymgme.2020.09.007. Retrieved from https://escholarship.umassmed.edu/oapubs/4429 Creative Commons License This work is licensed under a Creative Commons Attribution 4.0 License. This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Publications by UMMS Authors by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. Molecular Genetics and Metabolism 131 (2020) 325–340 Contents lists available at ScienceDirect Molecular Genetics and Metabolism journal homepage: www.elsevier.com/locate/ymgme Glutaric acidemia type 1: Treatment and outcome of 168 patients over three T decades ⁎ Kevin A. Straussa,b,c, , Katie B. Williamsa, Vincent J. Carsona,b, Laura Poskitta,b, Lauren E. Bowsera, Millie Younga, Donna L. Robinsona,
    [Show full text]
  • Defects in Amino Acid Catabolism and the Urea Cycle
    Handbook of Clinical Neurology, Vol. 113 (3rd series) Pediatric Neurology Part III O. Dulac, M. Lassonde, and H.B. Sarnat, Editors © 2013 Elsevier B.V. All rights reserved Chapter 181 Defects in amino acid catabolism and the urea cycle GEORG F. HOFFMANN* AND STEFAN KO¨ LKER Department of General Pediatrics, University Children’s Hospital Heidelberg, Heidelberg, Germany INTRODUCTION organizations can offer support. Since treatment is time- and cost-intensive, often lifelong, and mostly Defects in amino acid catabolism and the urea cycle performed at home, regular training and support of result in an accumulation of metabolites upstream of patients and their families is essential. Unfortunately, as the defective enzyme (amino acids (AAs), organic acids for all chronic diseases, average compliance with recom- and/or ammonia) causing intoxication. Phenylketonuria mendations has been found as low as 50%, e.g., in PKU. (PKU) is the most frequent AA disorder (AAD) in Individual defects in AA catabolism and the urea Caucasians. Breakdown of AAs results in the release cycle usually have a low prevalence except for some of ammonia that is detoxified by the urea cycle. Hyper- communities with high consanguinity rates. However, ammonemia is the biochemical hallmark of urea cycle the cumulative prevalence of these disorders is consider- defects (UCDs). able (i.e., at least> 1:2000 newborns; Schulze et al., After an uneventful pregnancy and an initially asymp- 2003). Detailed information on diagnosis, genetic test- tomatic period, the onset of symptoms in these disorders ing, treatment and follow-up is available at the following varies from neonatal metabolic decompensation to late online databases: onset in adulthood.
    [Show full text]
  • Evidence Table of Systematic Literature Search* According to SIGN Level
    027/018 – Glutarazidurie Typ I aktueller Stand: 06/2016 Evidence table of systematic literature search* according to SIGN Level Listed are published data since January 1st, 2011. For the time period from January 1st 1975 – December 31th 2010, please see the evidence table of systematic literature research generated for the 1st guideline revision in 2011 (page 36). Level 2++, 1++, 1+, 1-. None Level 2+. Evidence from well-conducted case-control or cohort studies with a low risk of confounding, bias, or chance and a moderate probability that the relationship is causal. First Title Study Design Patients (n) Clinical End Results / Conclusions Bias Confounding SIGN Author points (according to (according to Level GRADE) GRADE) Boy et al. A cross-sectional Cross sectional 30 patients Dystonia was BADS scores correlated with Effect of severe 2+ (2015) controlled study diagnosed by categorized using speed tests but not with tests dystonia might be Orphanet developmental study newborn screening the Barry-Albright- measuring stability or higher underestimated; J Rare Dis; of neuropsychological (n = 13), high-risk Dystonia Scale (BADS) cognitive functions 10:163 functions in patients screening (n = 3) or simple reaction time Developmental functions of False negative with glutaric aciduria targeted metabolic (SRT), continuous patients differed from findings are type I testing (n = 14) performance (CP), controls for SRT and VS but possible due to visual working not for VWM. Dystonic unequal sizes of n=13 dystonic memory patients were slower in SRT age groups patients, n=17 (VWM), visual-motor and CP but reached their asymptomatic coordination asymptote of performance patients (Tracking) and visual similar to asymptomatic search (VS).
    [Show full text]
  • United States Patent Office Patented Oct
    3,471,548 United States Patent Office Patented Oct. 7, 1969 2 CH-NH 3,471,548 GAMMA-AMNO-BETA-(PARA-HALOPHENYL)- B-( )-(H-CH-C OOR." BUTYRIC ACDS AND THEIR ESTERS Heinrich Keberle, Basel, Johann Werner Faigle, Riehen, in which formulae R has the meaning given above, R' and Max Wilhelm, Allschwil, Switzerland, assignors to represents an acyl group, such as a lower alkanoyl group Ciba Corporation, New York, N.Y., a corporation of (e.g. an acetyl, propionyl or butyryl group), a phenyl Delaware lower alkanoyl group (e.g. a phenylacetyl group) or a No Drawing. Filed June 30, 1964, Ser. No. 379,365 benzoyl group, and -COOR' represents an esterified Claims priority, application Switzerland, July 9, 1963, carboxyl group (R' representing for example a lower 8,537/63; May 22, 1964, 6,729/64 10 alkyl or phenyl lower alkyl group, such as a methyl, ethyl, Int. C. C07c 101/00, 101/02 propyl, butyl or benzyl group). U.S. C. 260-471 14 Claims The hydrolysis is carried out in the usual manner, for example in the presence of an aqueous acid or alkali at room temperature or with heating. ABSTRACT OF THE DISCLOSURE 15 Depending on the reaction conditions and starting ma New compounds of the formula terials used the final products are obtained in the free CH-NH form or in the form of their salts which are likewise in cluded in the present invention. Thus, for example, basic, R-( >- E-CH-COOH neutral, acid or mixed salts, possibly also hemi-, mono-, R=halogen, e.g.
    [Show full text]